Cargando…
Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148959/ https://www.ncbi.nlm.nih.gov/pubmed/37130465 http://dx.doi.org/10.1016/j.ejca.2023.03.036 |
| _version_ | 1785035073210286080 |
|---|---|
| author | Baba, Atsunori Tokunaga, Takuya Sakasegawa, Koichi Kanekura, Takuro Tsubouchi, Hirohito |
| author_facet | Baba, Atsunori Tokunaga, Takuya Sakasegawa, Koichi Kanekura, Takuro Tsubouchi, Hirohito |
| author_sort | Baba, Atsunori |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10148959 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101489592023-05-01 Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis Baba, Atsunori Tokunaga, Takuya Sakasegawa, Koichi Kanekura, Takuro Tsubouchi, Hirohito Eur J Cancer Letter to the Editor Elsevier Ltd. 2023-07 2023-04-30 /pmc/articles/PMC10148959/ /pubmed/37130465 http://dx.doi.org/10.1016/j.ejca.2023.03.036 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Baba, Atsunori Tokunaga, Takuya Sakasegawa, Koichi Kanekura, Takuro Tsubouchi, Hirohito Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis |
| title | Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis |
| title_full | Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis |
| title_fullStr | Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis |
| title_full_unstemmed | Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis |
| title_short | Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis |
| title_sort | letter re: sars-cov-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: brief report of a tyme network safety analysis |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148959/ https://www.ncbi.nlm.nih.gov/pubmed/37130465 http://dx.doi.org/10.1016/j.ejca.2023.03.036 |
| work_keys_str_mv | AT babaatsunori letterresarscov2vaccineinpatientswiththymicepithelialtumourswithandwithoutactiveorpreexistingautoimmunedisordersbriefreportofatymenetworksafetyanalysis AT tokunagatakuya letterresarscov2vaccineinpatientswiththymicepithelialtumourswithandwithoutactiveorpreexistingautoimmunedisordersbriefreportofatymenetworksafetyanalysis AT sakasegawakoichi letterresarscov2vaccineinpatientswiththymicepithelialtumourswithandwithoutactiveorpreexistingautoimmunedisordersbriefreportofatymenetworksafetyanalysis AT kanekuratakuro letterresarscov2vaccineinpatientswiththymicepithelialtumourswithandwithoutactiveorpreexistingautoimmunedisordersbriefreportofatymenetworksafetyanalysis AT tsubouchihirohito letterresarscov2vaccineinpatientswiththymicepithelialtumourswithandwithoutactiveorpreexistingautoimmunedisordersbriefreportofatymenetworksafetyanalysis |